PL378857A1 - Podwójnie skręcone oligonukleotydy interferujące z mRNA genu WNT1 (siRNA) stosowane w celu hamowania poliferacji komórek nowotworowych - Google Patents

Podwójnie skręcone oligonukleotydy interferujące z mRNA genu WNT1 (siRNA) stosowane w celu hamowania poliferacji komórek nowotworowych

Info

Publication number
PL378857A1
PL378857A1 PL378857A PL37885706A PL378857A1 PL 378857 A1 PL378857 A1 PL 378857A1 PL 378857 A PL378857 A PL 378857A PL 37885706 A PL37885706 A PL 37885706A PL 378857 A1 PL378857 A1 PL 378857A1
Authority
PL
Poland
Prior art keywords
polypheration
wnt1
sirna
mrna
gene
Prior art date
Application number
PL378857A
Other languages
English (en)
Inventor
Maciej Wieczorek
Joanna Wietrzyk
Anna Nasulewicz
Katarzyna Szczaurska
Original Assignee
Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością filed Critical Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL378857A priority Critical patent/PL378857A1/pl
Priority to EP07709261A priority patent/EP1984498A2/en
Priority to CA002640082A priority patent/CA2640082A1/en
Priority to CNA2007800118637A priority patent/CN101421398A/zh
Priority to AU2007210325A priority patent/AU2007210325A1/en
Priority to PCT/PL2007/000006 priority patent/WO2007089161A2/en
Publication of PL378857A1 publication Critical patent/PL378857A1/pl
Priority to ZA200806563A priority patent/ZA200806563B/xx
Priority to US12/221,063 priority patent/US20090264510A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL378857A 2006-01-31 2006-01-31 Podwójnie skręcone oligonukleotydy interferujące z mRNA genu WNT1 (siRNA) stosowane w celu hamowania poliferacji komórek nowotworowych PL378857A1 (pl)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PL378857A PL378857A1 (pl) 2006-01-31 2006-01-31 Podwójnie skręcone oligonukleotydy interferujące z mRNA genu WNT1 (siRNA) stosowane w celu hamowania poliferacji komórek nowotworowych
EP07709261A EP1984498A2 (en) 2006-01-31 2007-01-31 DOUBLE HELICAL OLIGONUCLEOTIDES INTERFERING WITH mRNA USED AS EFFECTIVE ANTICANCER AGENT
CA002640082A CA2640082A1 (en) 2006-01-31 2007-01-31 Double helical oligonucleotides interfering with mrna used as effective anticancer agent
CNA2007800118637A CN101421398A (zh) 2006-01-31 2007-01-31 以双螺旋寡核酸干扰mRNA作为有效的抗癌剂
AU2007210325A AU2007210325A1 (en) 2006-01-31 2007-01-31 Double helical oligonucleotides interfering with mRNA used as effective anticancer agent
PCT/PL2007/000006 WO2007089161A2 (en) 2006-01-31 2007-01-31 DOUBLE HELICAL OLIGONUCLEOTIDES INTERFERING WITH mRNA USED AS EFFECTIVE ANTICANCER AGENT
ZA200806563A ZA200806563B (en) 2006-01-31 2008-07-28 Double helical oligonucleotides interfering with mRNA used as effective anticancer agent
US12/221,063 US20090264510A1 (en) 2006-01-31 2008-07-30 Double helical oligonucleotides interfering with mRNA used as effective anticancer agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL378857A PL378857A1 (pl) 2006-01-31 2006-01-31 Podwójnie skręcone oligonukleotydy interferujące z mRNA genu WNT1 (siRNA) stosowane w celu hamowania poliferacji komórek nowotworowych

Publications (1)

Publication Number Publication Date
PL378857A1 true PL378857A1 (pl) 2007-08-06

Family

ID=38327790

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378857A PL378857A1 (pl) 2006-01-31 2006-01-31 Podwójnie skręcone oligonukleotydy interferujące z mRNA genu WNT1 (siRNA) stosowane w celu hamowania poliferacji komórek nowotworowych

Country Status (8)

Country Link
US (1) US20090264510A1 (pl)
EP (1) EP1984498A2 (pl)
CN (1) CN101421398A (pl)
AU (1) AU2007210325A1 (pl)
CA (1) CA2640082A1 (pl)
PL (1) PL378857A1 (pl)
WO (1) WO2007089161A2 (pl)
ZA (1) ZA200806563B (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011008117A2 (en) 2009-07-12 2011-01-20 Celon Pharma Sp. Z.O.O. The use of a sirna oligonucleotide

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3330377A1 (en) * 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CN102380099A (zh) * 2011-06-15 2012-03-21 中山大学肿瘤防治中心 Wnt2在制备抑制食管癌的药物的应用
CN107460197A (zh) * 2016-08-18 2017-12-12 广州市锐博生物科技有限公司 用于抑制COPS5靶基因mRNA表达的寡核酸分子及其成套组合物
CN114464259B (zh) * 2022-01-14 2024-03-29 郑州大学 一种靶向PD-1 mRNA反义脱氧寡核苷酸的筛选方法及应用
CN116825199A (zh) * 2023-02-21 2023-09-29 王全军 筛选siRNA序列以降低脱靶效应的方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
AU2002329667A1 (en) * 2001-07-30 2003-02-17 Uta Griesenbach Specific inhibition of gene expression by small double stranded rnas
GB0328928D0 (en) * 2003-12-12 2004-01-14 Cancer Rec Tech Ltd Materials and methods relating to cell cycle control
US20060040883A1 (en) * 2004-05-14 2006-02-23 The Regents Of The University Of California Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011008117A2 (en) 2009-07-12 2011-01-20 Celon Pharma Sp. Z.O.O. The use of a sirna oligonucleotide

Also Published As

Publication number Publication date
ZA200806563B (en) 2009-07-29
AU2007210325A1 (en) 2007-08-09
CA2640082A1 (en) 2007-08-09
WO2007089161A2 (en) 2007-08-09
EP1984498A2 (en) 2008-10-29
US20090264510A1 (en) 2009-10-22
CN101421398A (zh) 2009-04-29
WO2007089161A3 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
IL202090A0 (en) METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA)
EP2094086A4 (en) IN VIVO ADMINISTRATION OF DOUBLE-STRANDED RNA TO A TARGET CELL
HK1221266A1 (zh) 單細胞中的基因表達分析
WO2009079532A3 (en) Down-regulation of gene expression using artificial micrornas
HK1200487A1 (en) Silencing of csn5 gene expression using interfering rna rna csn5
ZA201003235B (en) Use of oligonucleotides with modified bases in hybridization of nucleic acids
GB0805363D0 (en) Novel NRPS-PKS gene cluster and its manipulation and utility
WO2009079548A3 (en) Down-regulation of gene expression using artificial micrornas
EP1620560A4 (en) INTRODUCTION OF SIRNA TO CELLS USING POLYAMPHOLYTES
PL378857A1 (pl) Podwójnie skręcone oligonukleotydy interferujące z mRNA genu WNT1 (siRNA) stosowane w celu hamowania poliferacji komórek nowotworowych
EP2379711B8 (en) Target populations of oligodendrocyte precursor cells and methods of making and using same
BRPI0812037A2 (pt) Variantes de uma alfa-amilase com níveis de produção aperfeiçoados em processos de fermentação
WO2008137862A3 (en) Methods of using mir34 as a biomarker for tp53 functional status
EP2454371A4 (en) CHEMICAL MODIFICATION OF SMALL HAIRPIN RNA FOR THE INHIBITION OF GENE EXPRESSION
EP2470622A4 (en) REDUCTION OF HYDROGEN CONSUMPTION IN THE HYDROGENATION OF BIOCOMPONENT RAW MATERIALS
EP2201134A4 (en) GENE EXPRESSION SIGNATURES IN ENRICHED TUMOR CELL SAMPLES
EP2078198A4 (en) USE OF CELL SURFACE PRESENTATIONS IN HEF-CELL CATALYST SUPPLEMENTS
WO2009131887A3 (en) Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
HK1190306A1 (zh) 含有心源性因子的組合物和相關方法、細胞，以及所述組合物、方法和細胞的應用
PT2695945E (pt) Métodos e reagentes para a transferência eficiente e dirigida de genes para monócitos e macrófagos
EP2481800A4 (en) NUCLEIC ACID APTAMER SPECIFICALLY BINDING TO PANCREATIC CANCER TISSUES OR CELLS AND USE THEREOF
EP2265717A4 (en) USE OF RNSI TO OBTAIN NEGATIVE REGULATION OF ENDOGENOUS GENE IN COMBINATION WITH THE USE OF SENS BUILDING PRODUCT TO OBTAIN EXPRESSION OF DESIRED POLYNUCLEOTIDE
WO2009097351A9 (en) TAK1-D MEDIATED INDUCTION OF CELL DEATH IN HUMAN CANCER CELLS BY SPECIFIC SEQUENCE SHORT DOUBLE STRANDED RNAs
EP2352744A4 (en) SHORT HAIR NADEL RNA FOR GENE EXPRESSION INHIBITION
EP2066334A4 (en) RNAI METHODS AND COMPOSITIONS FOR STIMULATING PROLIFERATION OF CELLS WITH ADHESIVE BONDS

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)